Fierce Pharma
FEBRUARY 9, 2024
Novo Nordisk has reached confidential settlements with two Florida sellers of compounded versions of the mega-blockbuster semaglutide treatments Ozempic and Wegovy, the company said on Friday. | Novo Nordisk has reached confidential settlements with two Florida sellers of compounded versions of the mega-blockbuster semaglutide treatments Ozempic and Wegovy, the company said on Friday.
MedCity News
FEBRUARY 9, 2024
Metagenomi finds novel gene-editing tools by mining microbial samples from around the world. Already partnered with Moderna and Ionis Pharmaceuticals, the company said its IPO cash will support ongoing preclinical research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 9, 2024
A year into a dire shortage of essential cancer medicines in the U.S., the American Society of Clinical Oncologists (ASCO) is again pushing Congress to act to end the crisis. | The oncology drug supply crisis has entered its second year, and doctors still face "impossible choices" without access to standard-of-care therapies, ASCO's chief medical officer, Dr.
MedCity News
FEBRUARY 9, 2024
Everly Health has formed a partnership with the National Kidney Foundation to improve education about chronic kidney disease. It has also expanded its diabetes monitoring and kidney health testing suite for health plans and employers.
Fierce Pharma
FEBRUARY 9, 2024
As Catalent gets ready to join the Novo fold, the contract manufacturing juggernaut continues to slide on its diminishing COVID-19 business. | Despite some turbulence at Catalent, including an 11% sales drop for the quarter, investors still seem to be buzzed about the stock after this week’s announcement that Novo Holdings is buying out the CDMO for $16.5 billion.
MedCity News
FEBRUARY 9, 2024
From our experience providing identity management services to healthcare SaaS companies, here are five rules for building more secure SaaS applications. The list can serve as a guide either for healthcare organizations looking to move key operations to SaaS or to makers of SaaS applications for healthcare customers.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 9, 2024
AppliedVR released study results demonstrating VR’s ability to help patients suffering from chronic low back pain. The technology was able to increase participants’ brain coherence and help them achieve a slower breathing rate — two metrics associated with reduced pain.
pharmaphorum
FEBRUARY 9, 2024
The combination of drugs for hypertension and software to personalise dosing to an individual patient has been shown to deliver improved blood pressure control and adherence to therapy in a pilot study.
MedCity News
FEBRUARY 9, 2024
With the PTC model, providers can remain independent, continue “driving the bus,” generate revenue for their practice, treat more patients virtually and scale their practice like never before.
Pharmaceutical Commerce
FEBRUARY 9, 2024
A dive into the intricacies of how to ensure a long-running event stays fresh and relevant to the needs of the pharmaceutical industry.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
MedCity News
FEBRUARY 9, 2024
The new era of full-stack compute-enabled bio companies will drive incredible advances in human health.
Pharmaceutical Technology
FEBRUARY 9, 2024
Pharma CEOs defended their high prescription drug costs, stating that the current prices are necessary for continued innovation.
PharmaVoice
FEBRUARY 9, 2024
After a big 2023, Yoshi Shitaka said the company is banking on gene therapies, KRAS degraders and more to keep the momentum.
Pharmaceutical Technology
FEBRUARY 9, 2024
AstraZeneca has reported a significant 81% rise in profit after tax, reaching $5.96bn for FY 2023 from $3.29bn in the previous year.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmaTimes
FEBRUARY 9, 2024
The rare neurodevelopmental condition CDKL5 is characterised by early-onset epilepsy
Pharmaceutical Technology
FEBRUARY 9, 2024
Boehringer has entered a strategic collaboration with CBmed to expedite the translation of cancer treatment approaches into new therapies.
PharmaTech
FEBRUARY 9, 2024
The three non-commercial developers of ATMPs will benefit from enhanced support from the agency.
Pharmaceutical Technology
FEBRUARY 9, 2024
Nippon will pay $10m upfront and up to $275m in milestone-based payments for the developmental and commercial rights to Vicore’s C21 in Japan.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MedCity News
FEBRUARY 9, 2024
Check out news from Health Wildcatters, Rivia Health, Apella, and more.
PharmaTimes
FEBRUARY 9, 2024
OART is increasingly emerging to assess and adapt treatment for cancer patients
Impetus Digital
FEBRUARY 9, 2024
At Impetus, we’re serious about our commitment to the planet. We have been planting trees across Canada and actively working towards reducing our emissions and reaching carbon neutrality since 2021. As a relatively small company, with no dedicated Sustainability Officer, we are taking a phased approach to becoming carbon-neutral by 2030. We’re excited to share that Phase 1 has officially been implemented!
Pharmaceutical Commerce
FEBRUARY 9, 2024
New collaboration seeks to take a significant step in the development of targeted treatments for solid tumors and an expansion of opportunities in the growing antibody-drug conjugate market.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
FEBRUARY 9, 2024
Synlogic has slashed nearly all its staff and launched a strategic review after its lead drug for rare disease phenylketonuria failed a phase 3 trial
PharmExec
FEBRUARY 9, 2024
The use of artificial intelligence (AI) in drug development has been hampered by issues that have caused a gap between AI’s potential and its full utilization in this space.
Pharmaceutical Technology
FEBRUARY 9, 2024
Novo Nordisk’s plans to buy Catalent has raised objections related to the risk of drug shortages, manufacturing standards, and antitrust violations.
PharmExec
FEBRUARY 9, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
FEBRUARY 9, 2024
BioNTech has entered into a strategic partnership with Autolus Therapeutics to progress the development of CAR-T cell therapy programmes.
PharmExec
FEBRUARY 9, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
FEBRUARY 9, 2024
The Phase I trial for evaluating Hemogenyx’s CAR-T therapy to treat acute myeloid leukaemia has been cleared to begin in the US.
Pharmacy Times
FEBRUARY 9, 2024
The prevalence of hypertension continues to increase amongst adults in the United States, leading to other cardiovascular conditions. Lifestyle changes and medication adherence are essential for appropriate hypertension management.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
249 
Let's personalize your content